Hydromer Reports Q1 Revenue Decline Amid Strategic Investments

Hydromer, Inc., a medical device coatings technology company, reported preliminary unaudited financial results for the first quarter of 2025, revealing a strategic approach to managing short-term financial challenges while positioning for future growth.

The company reported quarterly revenue of $1.0 million, a 9% decrease from the same period in 2024. This decline stems primarily from legacy customer attrition and typical delays in onboarding new medical coating programs. Net income for the quarter dropped 64% to $112,000, reflecting both reduced revenue and continued investment in product development and commercial infrastructure.

CEO Michael Torti emphasized the company's commitment to long-term strategic objectives, noting that while current financial metrics show contraction, the organization remains focused on enhancing its product pipeline and expanding into higher-value markets. The management team has been methodically addressing financial record-keeping and operational efficiency.

Notably, Hydromer has postponed a comprehensive U.S. GAAP audit, determining that such an undertaking would not be a prudent use of current capital resources. Instead, the company will maintain accurate internal financial records and reassess a full audit as its financial position evolves.

The company continues to leverage its four-decade expertise in surface modification technologies, maintaining compliance with FDA, GMP, and ISO standards. Hydromer remains dedicated to developing innovative coating solutions for medical devices and other industries, with a global customer base spanning the United States, Europe, and Asia-Pacific.